Summary
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
History
Corbus Pharmaceuticals was founded in 2012 and is headquartered in Norwood, MA with additional offices in Princeton, NJ and London, UK. We are focused on the development of novel therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases with high unmet medical need. Our lead therapeutic candidate, lenabasum, is being developed for the treatment of systemic sclerosis, cystic fibrosis, dermatomyositis and systemic lupus erythematosus.
Mission
Our mission is to develop, manufacture, and commercialize novel therapeutics to improve the lives of patients suffering from rare and serious inflammatory and fibrotic diseases, with a focus on meeting their unmet medical needs.
Vision
To become a leader in the development and commercialization of innovative, patient-focused therapies that transform the lives of those living with rare, chronic and serious inflammatory and fibrotic diseases.
Key Team
Ted Jenkins (Sr. Director of Investor Relations & Corp. Communications)
Ms. Lindsey Smith (Head of Corp. Communications & Patient Advocacy)
Scott Constantine (Sr. Director & Head of Clinical Operations)
Ms. Christina Bertsch (Head of HR)
Dr. Rachael Brake Ph.D. (Chief Scientific Officer)
Recognition and Awards
Corbus Pharmaceuticals has been a recipient of numerous awards, including the Financial Times’ US Innovative Lawyers Award, the EY Entrepreneur of the Year Award, and most recently, the SCRIPU Awards’ Best Innovation Award. We have also been named to the 2016, 2017 and 2018 FiercePharma rankings of the top 10 most innovative biopharma companies in the world.
References
United States 